Related to Galapagos Deals Aim to Shore Up Drug Discovery

• GSK Furthers Interest in China through Pediatric Vaccines JV with Initial $32M Investment
  
• SAFC Completes $12M Plant Expansion
  
• GSK Puts Down $25M for Prosensa’s Mid-Stage Candidate for Duchenne Muscular Dystrophy
  
• Galapagos and Merck & Co. Expand Existing Metabolic Disease Alliance to Cover Atherosclerosis
  
• GSK Obtains FDA Nod for HPV Vaccine
  
• GSK’s Seasonal Flu Vaccine Green-Lighted for Use in Children
  
• GSK to Exploit SuperGen’s Epigenetics Expertise in Cancer Collaboration
  
• Genmab and GSK Achieve Accelerated FDA Clearance of CLL Drug
  
• Novartis to Invest $1.25B in Two New Facilities in China
  
• arGEN-X Opens R&D Center in Flanders for Camelid-Derived Antibodies
  
• GSK Signs On Astex in Broad Partnership for About $33M Up Front
  
• Talecris Pours $268.7M into Production Plant in North Carolina
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Oxagen Raises £16M to Continue Clinical Development of CRTH2 Antagonist against Asthma
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Novartis Inaugurates $1B U.S. Cell Culture Flu Vaccine Facility
  
• EU Gives Dynavax’ German Manufacturing Plant the Nod for Commercial Production of HBV Vaccine
  
• GSK to Use Horizon Discovery’s Cell Lines for Cancer-Related Metabolomics Research
  
• GATC’s New U.K. Sequencing Lab to Offer Overnight Service
  
• Human Genome Sciences and GSK’s Lupus Candidate Hits the Mark in Second Phase III Trial